News

The provision, part of the Senate budget bill, was described as “a blatant giveaway to the pharmaceutical industry that would keep drug prices high for patients while draining $5 billion in taxpayer ...
The pharmaceutical industry’s lobbying muscle scored a high-stakes victory on Monday when the Senate parliamentarian reversed a previous decision and ruled that the Optimizing Research Progress Hope ...
PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.
Diversified Trust Co increased its stake in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.8% in the 1st quarter, HoldingsChannel.com reports. The firm owned 6,069 shares of the company’s stock after ...
Recent oncology breakthroughs showcase innovative treatments and approvals, enhancing patient outcomes in CLL, RCC, NSCLC, ...
Despite major advances, real-world data show diminishing survival outcomes and treatment-limiting toxicities in second line ...